Search the Newsreel

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat

Sanjit Biswas, Samsara CEO, sells $10.1m in stock

Sanjit Biswas, CEO of Samsara Inc. (NASDAQ:IOT), sold approximately $10.1 million worth of Class A Common Stock through pre-arranged trading plans between August 4 and August 6, 2026. These sales, conducted via the Biswas Family Trust and other trusts, involved a total of 262,900 …

Caesars Casino Bonus Code ROTOCASLAUNCH (August 2026): $1k & 2.5K Rewards Credits

The Caesars Casino bonus code ROTOCASLAUNCH offers new players in eligible states a welcome package including a $10 no-deposit bonus, a 100% deposit match up to $1,000, and 2,500 Caesars Rewards Credits. This promotion provides both immediate play value and long-term benefits through its …

OZYASAR TEL (OZYSR) Hisse Senedi

LENSAR (NASDAQ:LNSR) Upgraded at Wall Street Zen

Wall Street Zen upgraded LENSAR (NASDAQ:LNSR) from "sell" to "hold," aligning with the overall analyst consensus of "Hold" and an $11.00 price target. This upgrade follows LENSAR's positive quarterly earnings, which surpassed revenue and EPS expectations. The company also saw increased institutional investment and …

LENSAR (LNSR) Stock Profitability Breakthrough Faces Questions Over Margin Durability

Pentwater Capital reveals 5.6% Caesars Entertainment (CZR) position in Schedule 13G

Pentwater Capital Management LP and Matthew Halbower have reported a passive ownership stake of 5.6% in Caesars Entertainment, Inc. (CZR) common stock. This stake represents 11,465,000 shares out of 203,693,576 shares outstanding as of May 27, 2026. The reporting persons share both voting and …

Caesars Entertainment, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Caesars Entertainment, Inc. (CZR) on August 14, 2026. The filing indicates a proposed sale of 59,507 shares of common stock, acquired as restricted stock units on February 17, 2026, with an aggregate market value …

LENSAR® Reports Second Quarter 2026 Results and Provides Business Update

LENSAR, Inc. announced strong financial results for Q2 2026, including an 18% increase in total revenue and a 20% rise in recurring revenue compared to Q2 2025. The company placed 10 ALLY Robotic Cataract Laser Systems, bringing the total installed base to 215, and …

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research

Zacks Research has upgraded Sarepta Therapeutics (NASDAQ:SRPT) from a "strong sell" to a "hold" rating, contributing to a mixed analyst sentiment that results in an overall "Hold" consensus with a $25.06 price target. The company's shares opened at $18.42, with a market cap of …

Saregama India Ltd. Share Price Today - Saregama India Ltd. Stock Price Live NSE/BSE

Essar Shipping Ltd. Share Price Update: Peer Comparison

Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value

Sarepta Therapeutics, Inc. has filed a Form 13F as an institutional investment manager, detailing one information table entry with an aggregate reported value of $0. The filing, signed by Executive Vice President and CFO Ryan Wong, indicates no other included managers. This quarterly report …

Sarla Performance Fibers Share Price Target 2027 to 2030

Gr. Sarantis S.A. announces Annual dividend, payable on May 10, 2025

Samsara’s 38% quarter outruns software peers, while volume still lags the rebound

IOT added 9.7% for the week and closed 27.5% above its weekly Trend Line, but the latest 23.1M-share volume leaves participation short of full confirmation.

Sarthak Metals Publishes Q1 FY27 Unaudited Results in National and Regional Dailies

Salasar Techno Engineering consolidated net profit declines 41.36% in the June 2026 quarter

Samsara (IOT) Is Up 7.6% After Strong Subscription-Driven ARR Beat And Efficient Customer Acquisition – What's Changed

Lensar Returns to Profit in Q2 on Strong Demand for ALLY Cataract System

Lensar, Inc. reported strong financial results for Q2 2026, returning to profit with $3.5 million in net income, up from a loss the previous year. The company saw an 18% increase in revenue to $16.5 million, driven by demand for its ALLY Robotic Cataract …

Gr. Sarantis S.A.: Revenue and Earnings Analysts Forecasts Revisions | SAR | GRS204003008

Why Is Asara Resources (ASX:AS1) Stock Down Today?

Flour Mills C. Sarantopoulos SA Revenue Breakdown – ATHEX:KYSA

LENSAR (LNSR) swings to profit on $39.9M H1 net income and $10M merger fee

Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?

Sarepta Therapeutics recently tightened its 2026 revenue guidance to $1.2 billion to $1.3 billion and announced second-quarter results and pipeline updates. Despite a 15.38% share price jump over the last 7 days, the stock is down 13.75% year-to-date and 83.87% over three years. Analysts …

Carl Icahn Tops Fertitta's Caesars Offer With $34-Per-Share Bid

Billionaire investor Carl Icahn submitted a $34-per-share offer to acquire Caesars Entertainment in July 2026, surpassing Tilman Fertitta's existing $31-per-share deal. Icahn's interest in Caesars dates back to 2025, and despite his higher bid, Caesars' board continues to support Fertitta's offer, citing concerns about …

LENSAR (NASDAQ:LNSR) Posts Quarterly Earnings Results, Beats Expectations By $0.26 EPS

LENSAR (NASDAQ:LNSR) announced strong quarterly earnings, reporting $0.10 EPS, significantly beating analyst expectations of a ($0.16) loss. The company saw an 18% year-over-year revenue increase to $16.5 million, driven by growth in recurring and procedure revenues, and achieved a record adjusted EBITDA of $3.6 …

Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a beneficial ownership of 5,329,691 shares, or 5.05%, of Sarepta Therapeutics, Inc. common stock as of June 30, 2026. This reported amount includes 1,004,002 shares represented by Convertible Notes. Both entities share …

LENSAR Q2 Earnings Call Highlights

LENSAR reported strong second-quarter 2026 results with 18% revenue growth, driven by increasing adoption of its ALLY robotic laser cataract system. The company achieved its strongest quarterly adjusted EBITDA to date and saw significant increases in procedures and U.S. market share. LENSAR is focused …

Sarama Resources Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom

Sarepta Therapeutics (SRPT) saw its flagship gene therapy, ELEVIDYS, experience a fifth consecutive quarterly revenue decline, with analysts from H.C. Wainwright & Co. reiterating a Sell rating and a $5.00 price target. Despite this, the market reaction was muted, suggesting investors are assigning significant …

3 Reasons Investors Love Samsara (IOT)

3 Reasons Investors Love Samsara (IOT) What a fantastic six months it's been for Samsara. Shares of the company have skyrocketed 44.3%, hitting $40.04. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the …

Earnings call transcript: LENSAR beats on Q2 2026 profit, shares jump premarket

LENSAR Inc. reported strong Q2 2026 results, with adjusted earnings of $0.10 per share and revenue of $16.5 million, significantly beating analyst expectations. The company's stock jumped 16.85% premarket due to increased recurring revenue, procedure volume, and improved profitability, including a record adjusted EBITDA …